AllergyTalk Episode 63: Does Hereditary Angioedema Cause Muscle Injury?
AllergyTalk is a podcast designed to provide easy access to research summaries from Allergy Watch and recommendations from subject matter experts in order to bring physicians up to date on the latest advances in the field of allergy and immunology.
Recorded: 7/9/2026
AllergyWatch issue: May/June 2026
Speakers: Gerald Lee, MD, FACAAI; Shyam Joshi, MD, FACAAI; Vivian Hernandez-Trujillo, MD, FACAAI
Listeners can earn credit by completing the posttest questions
Price: FREE for members and non-members
Accreditation
The American College of Allergy, Asthma & Immunology (ACAAI) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
Designation
The American College of Allergy, Asthma & Immunology (ACAAI) designates this enduring material for a maximum of .50 AMA PRA Category 1 CreditTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Additional information
Recent article on TriNetX studies
NYTimes article discussing the economics of gene therapy for rare diseases
Target Audience
Primary Care Providers
Fellows-in-Training
Learning Objectives
Upon completion of this podcast, the participant should be able to:
1. Summarize recent key developments in the field of allergy and immunology, and assess how these findings impact clinical practice in allergy/immunology management.
2. Demonstrate practical strategies for implementing current recommendations for allergy and immunology conditions, including specific tools and techniques that can be easily integrated into daily clinical workflows.
3. Evaluate the effectiveness of therapy implementation in their practice and employ strategies to monitor patient outcomes in accordance with the most current allergy and immunology guidelines.
Course summary
- 0.50 AMA PRA Category 1 Credit™
- 0.50 Attendance
All relevant financial relationships with ineligible companies have been mitigated.
Gerald Lee, MD
No relevant financial relationships with ineligible companies to disclose
Shyam Joshi, MD
No relevant financial relationships with ineligible companies to disclose
Vivian Hernandez-Trujillo, MD
Advisor: ARS, Bryn Pharma, DBV Technologies, Novartis, Kaleo Pharmaceuticals, , Pfizer, Takeda, Bayer
Speaker: ARS, CSL Behring, DBV Technologies, Takeda, Kaleo Pharmaceuticals
Consultant: Kaleo Pharmaceuticals, Kedrion, Bayer
Available Credit
- 0.50 AMA PRA Category 1 Credit™
- 0.50 Attendance

Facebook
X
LinkedIn
Forward